Takeda Pharmaceutical Expected to Post Fourth-Quarter Net Loss -- Earnings Preview

Dow Jones

May 07, 2025

By Kosaku Narioka

Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know:

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period.

REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows.

Shares have gained 3.2% so far this year after rising a 3.1% in 2024.

WHAT TO WATCH:

--Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs.

--Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion.

--Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

May 07, 2025 07:11 ET (11:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533856789"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533856789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533856789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533856789","market":"fut","top_or_hot":-1,"title":"Takeda Pharmaceutical Expected to Post Fourth-Quarter Net Loss -- Earnings Preview","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre>\n \n</pre>\n<p>\n  Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know: \n</p>\n<pre>\n \n</pre>\n<p>\n  NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period. \n</p>\n<pre>\n \n</pre>\n<p>\n  REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows. \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares have gained 3.2% so far this year after rising a 3.1% in 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs. \n</p>\n<p>\n  --Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion. \n</p>\n<p>\n  --Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 07:11 ET (11:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Expected to Post Fourth-Quarter Net Loss -- Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Expected to Post Fourth-Quarter Net Loss -- Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 19:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre>\n \n</pre>\n<p>\n  Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know: \n</p>\n<pre>\n \n</pre>\n<p>\n  NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period. \n</p>\n<pre>\n \n</pre>\n<p>\n  REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows. \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares have gained 3.2% so far this year after rising a 3.1% in 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs. \n</p>\n<p>\n  --Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion. \n</p>\n<p>\n  --Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 07:11 ET (11:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"POST","symbol_name":"Post Holdings","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533856789","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533856789","pubTimestamp":1746616260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know:. NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period.REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows.Shares have gained 3.2% so far this year after rising a 3.1% in 2024.--Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs.--Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion.--Margin trends will also be in focus after operating profit margin declined to 5.9% in ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"POST":"Post Holdings","TAK":"武田制药"},"translate_title":"武田制药预计第四季度净亏损——盈利预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1,"TAK":0.9},"content_text":"By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know: \n\n\n \n\n\n  NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period. \n\n\n \n\n\n  REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows. \n\n\n \n\n\n  Shares have gained 3.2% so far this year after rising a 3.1% in 2024. \n\n\n \n\n\n  WHAT TO WATCH: \n\n\n  --Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs. \n\n\n  --Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion. \n\n\n  --Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures. \n\n\n \n\n\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 07:11 ET (11:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}